Dell (back) is listed as active for Sunday night's game against the Lions. Dell, who worked fully Wednesday and Thursday, approached the contest listed as questionable after being limited in practice ...

Houston Texans wide receiver Tank Dell (back) is officially active for the Week 10 contest against the Detroit Lions on ...

Houston Texans wide receiver Tank Dell (back) is listed as questionable but is expected to suit up on Sunday evening to face ...

A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts. Chris Katje Biden Administration ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the price target to $361.00 from $376.00. Whitney Ijem has ...